Sequoia Financial Advisors LLC Makes New Investment in Avantor, Inc. (NYSE:AVTR)

Sequoia Financial Advisors LLC bought a new stake in Avantor, Inc. (NYSE:AVTR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,864 shares of the company’s stock, valued at approximately $255,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners lifted its holdings in Avantor by 2.2% in the first quarter. Boston Partners now owns 28,561,802 shares of the company’s stock valued at $729,298,000 after buying an additional 624,369 shares during the period. Canada Pension Plan Investment Board lifted its stake in shares of Avantor by 6.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock valued at $486,059,000 after purchasing an additional 1,463,695 shares during the period. 1832 Asset Management L.P. boosted its position in shares of Avantor by 1,634.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after purchasing an additional 8,038,451 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Avantor by 4.4% during the first quarter. Bessemer Group Inc. now owns 7,099,848 shares of the company’s stock worth $181,544,000 after purchasing an additional 297,534 shares during the period. Finally, Robeco Schweiz AG increased its holdings in Avantor by 5.0% in the second quarter. Robeco Schweiz AG now owns 6,006,985 shares of the company’s stock valued at $127,348,000 after purchasing an additional 287,717 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AVTR shares. TD Cowen boosted their target price on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Evercore ISI lowered their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Robert W. Baird reduced their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday. Wells Fargo & Company lowered their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $30.00 to $23.00 in a report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Price Performance

Shares of AVTR opened at $22.52 on Wednesday. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. Avantor, Inc. has a twelve month low of $16.63 and a twelve month high of $28.00. The stock has a market capitalization of $15.30 billion, a P/E ratio of 57.74, a P/E/G ratio of 2.93 and a beta of 1.33. The company has a 50 day moving average of $25.38 and a 200-day moving average of $24.22.

Insider Buying and Selling

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.